RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Real-world treatment patterns and clinical outcomes in Er+/Her2- metastatic breast cancer
Results from a multicountry retrospective medical record review
Kurosky, S., Mitra, D., Zanotti, G., & Kaye, J. (2016). Real-world treatment patterns and clinical outcomes in Er+/Her2- metastatic breast cancer: Results from a multicountry retrospective medical record review. Value in Health, 19(3), A137. https://doi.org/10.1016/j.jval.2016.03.1644
Although ET is the recommended treatment for most patients with ER+/HER2– MBC, a substantial proportion received CT, possibly due to the high prevalence of visceral disease in the study population. Median TTP on current therapies is < 1 year. These findings suggest a continuing unmet need for new treatments that extend TTP.